乳腺癌组织p16蛋白和VEGF的表达及其临床意义

目的　探讨乳腺癌组织中p16蛋白、VEGF的表达与乳腺癌临床病理指标及预后的关系。方法　采用SABC免疫组织化学技术 ,检测 5 3例乳腺癌标本中p16蛋白及VEGF的表达 ,结合临床病理和随访资料作统计分析。结果　 5 3例乳腺癌组织中p16蛋白的阳性表达率为 5 4 7%,其表达与患者的年龄、肿瘤大小、绝经状况、ER、PR的表达无关 (P >0 0 5 ) ,而与乳腺癌的组织学分级、TNM分期、淋巴结转移及 5年生存率相关 (P <0 0 5 ) ;VEGF的阳性表达率为 79 2 5 %,其表达与患者的年龄、肿瘤大小、绝经状况、ER、PR的表达、TNM分期及 5年生存率无显著相关性 (P >0 0 5 ) ,而与组织学分级及淋巴结转移密切相关 (P <0 0 5 )。结论　p16蛋白和VEGF的表达与乳腺癌的浸润、转移密切相关 ,可作为乳腺癌的生物学标记。p16可作为临床上判定乳腺癌预后的一个新指标。

Expression of p16 and VEGF in Breast Cancer Tissue and Their Clinical Significance

Objective To investigate the expression of p16 and VEGF in breast cancer and their correlation with clinicopathological parameters of breast cancer and the patients' prognosis. Methods Expressions of p16 and VEGF were determined in 53 breast cancer tissues with SABC immunohistochemical method, and clinic pathological data of the patients were collected and used to make statistical analysis. Results Positive rates of p16 and VEGF in breast cancer were 54 7%(29/53) and 79 25%(42/53), respectively. p16 expression was not associated with patient's age, tumor size, menopause, and expression of ER and PR (P>0 05). A negative correlation was found between p16 expressions and the histological grade, clinical TNM stage, lymph-node metastasis and 5-years survival rate(P<0 05). VEGF expression was not associated with patient's age, tumer size, menopause, expression of ER and PR, TNM stage and 5-years survival (P>0 05), but associated with histological grade and lymph-node metastasis(P<0 05). Conclusions The expression of p16 and VEGF was related to local invasion and lymph-node metastasis of breast carcinoma, and they could be used as a biologic marker of breast cancer. p16 may serve as an important indicator to estimate prognosis of the patients with breast cancer.